Hansoh Pharmaceutical's (HKG:3692) biologics license application for HS-20093 for injection was accepted by China's National Medical Products Administration.
The acceptance is for the treatment of osteosarcoma patients 12 years of age and above who have failed at least two prior lines of therapy, a Thursday bourse filing said.